Dr. Saad Z. Usmani, MD

Dr. Usmani practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Usmani's NPI, 1962601526, was assigned on July 13, 2007. Dr. Usmani graduated from Allama Iqbal Medical College in 2002. Dr. Usmani holds North Carolina license 2013-01066.

Dr. Usmani's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Usmani's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Usmani to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Usmani practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Usmani's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Usmani is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Usmani's licenses on file in 9 states: North Carolina, Florida, New Jersey, South Carolina, Connecticut, New York, Michigan, Texas and Arkansas.

Dmand AI lists colorectal cancer, multiple myeloma and prostate cancer among the conditions Dr. Usmani treats.

CMS data shows 391 Medicare services from Dr. Usmani across 3 procedure codes in 2024, for 158 Medicare patients. Medicare paid $52,359 for them.

CMS counts 158 Medicare patients who saw Dr. Usmani in 2024. The largest group is 65 to 74, with 76 patients. 73% of them have high cholesterol, and 72% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Usmani's median patient age at 72, with 45% women.

In 2024, Dr. Usmani wrote 456 Medicare Part D claims for 79 patients. 75% of them were for generic drugs. CMS names the drug for 340 of them, across 10 drugs with 11 or more claims each, at $1,196,555 in total drug cost. In 2023, CMS named 290 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Usmani for performance year 2024, reported as part of a group. Dr. Usmani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Usmani as offering telehealth.

Dmand AI links 256 papers to Dr. Usmani, published from 2010 to 2025. 2023 was the busiest year, with 23. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Antibodies, Monoclonal. Dr. Usmani has published most often in Blood Cancer J. Dr. Usmani's most frequent co-authors are Shaji K. Kumar, MD, Bart Barlogie, MD and Alexander M. Lesokhin, MD.

Dmand AI links Dr. Usmani to 54 clinical trials, 16 of them phase 2 studies. 21 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Amyloidosis. Janssen Research & Development, LLC sponsors the most, 11. Open Payments lists research payments to Dr. Usmani that name 1 trial.

CMS Open Payments shows 689 general payments to Dr. Usmani from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 63% of the total. Janssen Research & Development, LLC paid the most, $179,028. It also lists 19 research payments totaling $16,764 from 2016 to 2023, naming 1 clinical trial.

Dmand AI lists 5 awards for Dr. Usmani, most recently Giants in Cancer Care in 2025.

Dr. Usmani graduated from Allama Iqbal Medical College in 2002. Dr. Usmani is a member of AACR, ACP, American Society for Transplantation and Cellular Therapy, ASCO, ASH and International Myeloma Society.

Dr. Usmani is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.